2010
DOI: 10.17533/udea.iatreia.8452
|View full text |Cite
|
Sign up to set email alerts
|

Tratamiento de los defectos de la pared abdominal (gastrosquisis y onfalocele) en el Hospital Universitario San Vicente de Paúl, Medellín, 1998-2006

Abstract: Introducción: la gastrosquisis y el onfalocele son malformaciones de la pared abdominal en neonatos que, a pesar de sus grandes diferencias, tienen en común el hecho de ser enfermedades graves caracterizadas por la herniación de las vísceras intrabdominales a través de un defecto de la pared abdominal. Los niños con estas enfermedades se presentan como emergencias quirúrgicas que plantean un reto difícil para el cirujano tratante. Tienen una tasa de mortalidad que oscila entre 20- 40%, aun con el tratamiento a… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2014
2014
2016
2016

Publication Types

Select...
2

Relationship

0
2

Authors

Journals

citations
Cited by 2 publications
(1 citation statement)
references
References 32 publications
0
1
0
Order By: Relevance
“…Despite powerful strides forward in the treatment of congenital anomalies, or birth defects, the benefits of these diagnostic and therapeutic advances have been largely confined to high-income countries (HICs), where many once fatal conditions can now be treated, with mortality rates under 10 %. In contrast, mortality rates from hospital-based data in low-and middle-income countries (LMICs) for common anomalies often rise to 20-85 % [2][3][4][5][6][7][8][9][10][11][12][13][14][15][16][17]. Patients with immediately life-threatening conditions may die in transit or at home, and never be entered into such hospital-based measures [18,19]; the resultant hidden mortality represents an oftunderestimated addition to the burden of disease.…”
Section: Introductionmentioning
confidence: 99%
“…Despite powerful strides forward in the treatment of congenital anomalies, or birth defects, the benefits of these diagnostic and therapeutic advances have been largely confined to high-income countries (HICs), where many once fatal conditions can now be treated, with mortality rates under 10 %. In contrast, mortality rates from hospital-based data in low-and middle-income countries (LMICs) for common anomalies often rise to 20-85 % [2][3][4][5][6][7][8][9][10][11][12][13][14][15][16][17]. Patients with immediately life-threatening conditions may die in transit or at home, and never be entered into such hospital-based measures [18,19]; the resultant hidden mortality represents an oftunderestimated addition to the burden of disease.…”
Section: Introductionmentioning
confidence: 99%